Confronto
Lanreotid vs. Triptorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
108736-35-2
57773-63-4
Peso molecolare
1096.34 g/mol
1311.45 g/mol
Emivita
nessun dato
3 h
Sequenza
nessun dato
pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Meccanismo d'azione
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
3
Contraddizioni aperte
1
0
Eventi avversi documentati
2
3
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Lanreotid and Triptorelin?
- Lanreotid is classified as "Ricerca (altro)", while Triptorelin is classified as "Ricerca (altro)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or Triptorelin?
- The highest available evidence level is "RCT sull'uomo" for Lanreotid and "RCT sull'uomo" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and Triptorelin in Germany and the United States?
- Germania: Lanreotid — Su prescrizione, Triptorelin — Su prescrizione. Stati Uniti: Lanreotid — Su prescrizione, Triptorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.